BlackRock
TEVA icon

BlackRock’s Teva Pharmaceuticals TEVA Stock Holding History

BlackRock’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-5,000
Closed -$77K – 5045
2018
Q4 		$77K Buy
+5,000
New +$103K ﹤0.01% 4402
2014
Q2 		– Sell
-175,000
Closed -$9.25M – 3222
2014
Q1 		$9.25M Buy
+175,000
New +$8.09M 0.01% 691

Other funds holding TEVA

HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock's TEVA Position: Q1 2026 in Review

BlackRock increased its Teva Pharmaceuticals (TEVA) stake by 12% in Q1 2026, buying an estimated $220M and bringing the position to 65,136,464 shares worth $1.96B. The position accounts for 0.03% of the portfolio, ranked #423.

BlackRock first reported a position in TEVA in Q1 2014 and has held it in 49 quarters since. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • BlackRock held 65,136,464 shares of Teva Pharmaceuticals worth $1.96B as of Q1 2026.
  • BlackRock bought 6,833,776 Teva Pharmaceuticals shares in Q1 2026, an estimated $220M.
  • Teva Pharmaceuticals made up 0.03% of BlackRock's portfolio in Q1 2026, its #423 holding.
  • BlackRock first reported a position in Teva Pharmaceuticals in Q1 2014 and has held it in 49 quarters since.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.